The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Checkpoint inhibitor consolidation after definitive chemoradiation for stage III non–small cell lung cancer: Real-world experience in a large academic health system.
 
Nikhil Yegya-Raman
No Relationships to Disclose
 
Cole Friedes
No Relationships to Disclose
 
Lova Sun
Consulting or Advisory Role - HMP; MJH Life Sciences; Regeneron
 
Melina Elpi Marmarelis
Stock and Other Ownership Interests - Bluebird Bio; Gilead Sciences; Johnson & Johnson; Merck; Pfizer; Portola Pharmaceuticals
Honoraria - AstraZeneca; Blueprint Medicines; Blueprint Medicines; Health Advances (I); Janssen Oncology; Novocure; Takeda; Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Ikena Oncology
Research Funding - AstraZeneca (Inst); Lilly (Inst); Trizell (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Novocure
Other Relationship - Novartis
 
William C. Levin
No Relationships to Disclose
 
Keith A. Cengel
Stock and Other Ownership Interests - Symphotek; Symphotek
Consulting or Advisory Role - Novocure
Patents, Royalties, Other Intellectual Property - US20190099491A1 Sensitizing Cells to Proton Radiation; US9999779B2 Cell, tissue and organ protection using a magnetic field
Travel, Accommodations, Expenses - Novocure
 
Brian Lally
No Relationships to Disclose
 
Christopher Davella
No Relationships to Disclose
 
John A. Kosteva
No Relationships to Disclose
 
Aditi Puri Singh
Consulting or Advisory Role - Precision HEOR (I)
 
Roger B. Cohen
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Cantargia AB; Coherus Biosciences; Fstar Therapeutics; Heat Biologics; Xencor
Research Funding - AstraZeneca (Inst); Celldex (Inst); Codiak Biosciences (Inst); F-Star Biotechnology (Inst); Genocea Biosciences (Inst); Heat Biologics (Inst); Innate Pharma (Inst); Macrogenics (Inst); Merck (Inst); Xencor (Inst)
 
Charu Aggarwal
Consulting or Advisory Role - AstraZeneca; BeiGene; Blueprint Genetics; Boehringer Ingelheim; Celgene; Daiichi Sankyo/Astra Zeneca; Eisai; Genentech; Janssen; Lilly; Merck; Pfizer; Sanofi/Regeneron; Shionogi; Turning Point Therapeutics
Speakers' Bureau - AstraZeneca (I); Roche/Genentech (I)
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Incyte (Inst); Macrogenics (Inst); Merck Sharp & Dohme (Inst)
 
Christine Ciunci
Honoraria - Imedex; Imedex; Merck
Research Funding - Bristol Myers Squibb (Inst); Celgene (Inst); MacroGenics (Inst); Merck (Inst)
 
Abigail T. Berman
Employment - CVS Health
Honoraria - Imedex; Varian Medical Systems
Consulting or Advisory Role - AstraZeneca
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - Varian Medical Systems
 
Corey J. Langer
Honoraria - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Lilly/ImClone; Merck; Takeda Science Foundation
Consulting or Advisory Role - Abbott Biotherapeutics; ARIAD; AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; Cancer Support Community; Celgene; Clarient; Clovis Oncology; Genentech/Roche; Gilead Sciences; Lilly/ImClone; Merck; Novocure; Pfizer; Regeneron; Takeda
Research Funding - Advantagene (Inst); Amgen; Ariad (Inst); AstraZeneca; Celgene (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Inovio Pharmaceuticals (Inst); Johnson & Johnson/Janssen; Lilly; Merck (Inst); Stem CentRx (Inst); Trizell (Inst)
Other Relationship - Amgen; Lilly; OncoCyte; Peregrine Pharmaceuticals; Synta
 
Steven J. Feigenberg
No Relationships to Disclose